Last edition
News about "Kenneth Custer"
Lilly's Retatrutide Shows Strong A1C, Weight Reduction in Phase-III Diabetes Trial
Eli Lilly’s Retatrutide reduced A1C by up to two percent and delivered average weight loss of 36.6 lbs in its phase-III TRANSCEND-T2D-1 trial, with continued weight reduction observed through 40 weeks in type-II diabetes mellitus patients.
Kenneth Custer | 20/03/2026 | By News Bureau
Orforglipron by Lily Shows Significant Weight Loss and Cardiometabolic Gains in ATTAIN-1 Results
Orforglipron by Eli Lily demonstrated significant improvements across key cardiometabolic risk factors, supporting its potential as a treatment option for millions living with obesity.
Kenneth Custer | 18/09/2025 | By Dineshwori | 398
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy